Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Patients across Nebraska — from Adams County to smaller communities — are transforming their lives with FDA-approved GLP-1 medications through licensed telehealth. For many, it is the breakthrough they have been waiting for after years of struggling with traditional approaches. Our NE-licensed physicians evaluate your eligibility and build a personalized GLP-1 treatment plan designed for maximum results.
FDA-approved GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — are prescribed by board-certified physicians following evidence-based clinical protocols. The STEP 1 trial (NEJM 2021) confirmed −15.3% mean weight loss with semaglutide; the SURMOUNT-1 trial (NEJM 2022) confirmed −22.5% with tirzepatide.
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 5, 2026
Nebraska supports patients seeking transformative weight management through licensed telehealth. All providers hold active NE medical licenses and follow evidence-based treatment protocols for GLP-1 prescribing — ensuring your transformation is built on a solid medical foundation.
Select your Nebraska city to begin your health transformation. Licensed GLP-1 specialists are serving patients in every corner of the state.
The clinical evidence for FDA-approved GLP-1 receptor agonists comes from large phase III randomized controlled trials published in the New England Journal of Medicine:
Nebraska authorizes board-certified licensed physicians to prescribe FDA-approved GLP-1 medications via telehealth after a valid patient-physician relationship is established through an online consultation. GLP-1 receptor agonists are not DEA-scheduled controlled substances — no in-person visit is legally required in Nebraska.
Life-changing GLP-1 results extend beyond Nebraska — our transformation network covers all neighboring states and all 50 states nationwide.
Board-certified physicians offer GLP-1 telehealth consultations in every city across the state. Choose your city below for localized service information and eligibility details.
Local weight loss and GLP-1 providers serving the Nebraska area, based on Google Business listings.
1299 Farnam St %23302, Omaha, NE 68102
(531) 283-5400
5/5 ★ (16 reviews)
Visit website →Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Nebraska patients using semaglutide (Wegovy) achieve an average of 15% body weight loss over 68 weeks. Those on tirzepatide (Zepbound) see up to 22% average weight reduction over 72 weeks. Beyond the scale, patients report dramatic improvements in energy, blood pressure, blood sugar, and overall quality of life.
Most Nebraska patients notice reduced appetite within the first 1-2 weeks. Visible weight loss typically begins within the first month and accelerates with dose titration. The most significant transformation typically occurs between months 3-6, with continued improvement throughout treatment.
Yes. GLP-1 medications work through hormonal mechanisms that address the biological roots of excess weight — not just behavior. Many Nebraska patients who struggled for years with conventional approaches achieve breakthrough transformation with GLP-1 because it directly addresses appetite regulation and metabolic dysfunction.
GLP-1 transformation goes beyond weight loss. Nebraska patients experience measurable improvements in HbA1c, systolic blood pressure, triglycerides, LDL cholesterol, joint pain, sleep quality, and cardiovascular risk. The SELECT trial showed semaglutide reduced major cardiac events by 20% in at-risk patients.
Clinical evidence shows weight is often maintained during treatment. To sustain transformation after discontinuation, physicians recommend pairing GLP-1 therapy with lifestyle changes. Nebraska physicians offer ongoing support and maintenance dosing options to help patients preserve their results long-term.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
